Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer R Cochran

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
Journal of Molecular Recognition : JMR|January 4, 2011
Cystine-knot peptides engineered with specificities for α(IIb)β(3) or α(IIb)β(3) and α(v)β(3) integrins are potent inhibitors of platelet aggregationAdam P Silverman, Mihalis S Kariolis, Jennifer R Cochran
Journal of the American Chemical Society|June 10, 2016
In Vivo Site-Specific Protein Tagging with Diverse Amines Using an Engineered Sortase VariantJeff E Glasgow, Marc L Salit, Jennifer R Cochran
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2011
Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonistsDouglas S Jones, Ping-Chuan Tsai, Jennifer R Cochran
Journal of Molecular Biology|September 6, 2011
Discovery of improved EGF agonists using a novel in vitro screening platformBertrand H Lui, Jennifer R Cochran, James R Swartz
Trends in Biotechnology|August 5, 2008
Developing therapeutic proteins by engineering ligand-receptor interactionsDouglas S Jones, Adam P Silverman, Jennifer R Cochran
Trends in Biotechnology|April 9, 2026
Scientific breakthrough versus successful startup: teaching scientists to navigate bench to businessSherry Yang, Jennifer R Cochran, Rowan Chapman, et al.
Trends in Pharmacological Sciences|November 13, 2016
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer TreatmentJames R Kintzing, Maria V Filsinger Interrante, Jennifer R Cochran
Proceedings of the National Academy of Sciences of the United States of America|August 10, 2011
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrinNiv Papo, Adam P Silverman, Jennifer L Lahti, et al.
Cancer Research|March 12, 2009
Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjectsRichard H Kimura, Zhen Cheng, Sanjiv Sam Gambhir, et al.
Proteins|May 20, 2009
Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinityRichard H Kimura, Aron M Levin, Frank V Cochran, et al.
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
Journal of Molecular Recognition : JMR|January 4, 2011
Cystine-knot peptides engineered with specificities for α(IIb)β(3) or α(IIb)β(3) and α(v)β(3) integrins are potent inhibitors of platelet aggregationAdam P Silverman, Mihalis S Kariolis, Jennifer R Cochran
Journal of the American Chemical Society|June 10, 2016
In Vivo Site-Specific Protein Tagging with Diverse Amines Using an Engineered Sortase VariantJeff E Glasgow, Marc L Salit, Jennifer R Cochran
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2011
Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonistsDouglas S Jones, Ping-Chuan Tsai, Jennifer R Cochran
Journal of Molecular Biology|September 6, 2011
Discovery of improved EGF agonists using a novel in vitro screening platformBertrand H Lui, Jennifer R Cochran, James R Swartz
Trends in Biotechnology|August 5, 2008
Developing therapeutic proteins by engineering ligand-receptor interactionsDouglas S Jones, Adam P Silverman, Jennifer R Cochran
Trends in Biotechnology|April 9, 2026
Scientific breakthrough versus successful startup: teaching scientists to navigate bench to businessSherry Yang, Jennifer R Cochran, Rowan Chapman, et al.
Trends in Pharmacological Sciences|November 13, 2016
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer TreatmentJames R Kintzing, Maria V Filsinger Interrante, Jennifer R Cochran
Proceedings of the National Academy of Sciences of the United States of America|August 10, 2011
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrinNiv Papo, Adam P Silverman, Jennifer L Lahti, et al.
Cancer Research|March 12, 2009
Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjectsRichard H Kimura, Zhen Cheng, Sanjiv Sam Gambhir, et al.
Proteins|May 20, 2009
Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinityRichard H Kimura, Aron M Levin, Frank V Cochran, et al.
Pageof 11